Johnson Fistel Investigates Executive Liability for Multiple Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy BIIB?
Source: Globenewswire
- Shareholder Rights Investigation: Johnson Fistel is investigating potential breaches of fiduciary duty by executives at Avantor, Baxter, Biogen, and CarMax, which may lead shareholders to seek corporate governance reforms and fund recovery.
- Avantor Allegations: A lawsuit against Avantor claims that executives failed to disclose a decline in competitive positioning and negative competitive impacts, leading to shareholder misconceptions about the company's prospects, potentially affecting its stock price.
- Baxter Product Defects: Baxter's Novum LVP product is alleged to have systemic defects that pose serious risks to patients, and the company's inadequate response to these defects may result in significant legal and financial repercussions.
- Biogen Transparency Issues: Biogen is accused of overstating its efforts to enhance transparency and compliance controls, failing to disclose improper conduct in foreign operations, which could lead to regulatory scrutiny and reputational harm.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BIIB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BIIB
Wall Street analysts forecast BIIB stock price to rise
26 Analyst Rating
11 Buy
14 Hold
1 Sell
Moderate Buy
Current: 183.840
Low
143.00
Averages
204.45
High
246.00
Current: 183.840
Low
143.00
Averages
204.45
High
246.00
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
FDA Approves Biogen's New High-Dose Spinraza Regimen
- New Dosage Regimen: The US FDA has approved Biogen's new high-dose regimen for Spinraza, consisting of 50 mg/5 mL and 28 mg/5 mL doses, significantly enhancing treatment flexibility and efficacy.
- Accelerated Loading Phase: The new regimen allows individuals new to treatment to receive two 50 mg high-dose injections 14 days apart, followed by 28 mg maintenance doses every four months, thereby accelerating patient treatment progress.
- Transition for Low-Dose Patients: Patients switching from the low-dose regimen will follow their current dosing schedule every four months after a single high-dose loading phase, ensuring continuity and stability in their treatment.
- Clinical Study Support: The approval is supported by results from the phase 2/3 DEVOTE study, demonstrating significant advantages in treatment outcomes with the new dosing regimen, further solidifying Biogen's market position in spinal muscular atrophy.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: Biogen announced that its High Dose SPINRAZA (nusinersen) has been approved by the U.S. FDA for the treatment of spinal muscular atrophy (SMA), backed by over 10 years of clinical data to address ongoing community needs.
- Innovative Dosage Design: The high dose regimen includes 50 mg/5 mL and 28 mg/5 mL doses, designed to deliver a higher concentration of the drug through an accelerated loading phase and maintenance dosing, enabling faster treatment initiation for new patients.
- Clinical Trial Support: The FDA approval is based on data from the three-part Phase 2/3 DEVOTE study, which showed that treatment-naïve symptomatic infants receiving High Dose SPINRAZA experienced statistically significant improvements in motor function compared to a matched sham group from the ENDEAR study, demonstrating the treatment's efficacy.
- Broad Market Outlook: High Dose SPINRAZA will be available in the U.S. in the coming weeks and is also approved in the European Union, Switzerland, and Japan, expected to provide new treatment options for SMA patients globally, further solidifying Biogen's leadership in the neuromuscular disease space.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
FDA GREENLIGHTS NEW HIGH-DOSE TREATMENT PLAN FOR SPINRAZA® (NUSINERSEN) IN SPINAL MUSCULAR ATROPHY
FDA Approval: The FDA has approved a new high-dose regimen of Spinraza® (nusinersen) for the treatment of spinal muscular atrophy (SMA).
Treatment Impact: This approval is expected to enhance treatment options for patients suffering from SMA, a genetic disorder affecting muscle strength and movement.
See More
Biogen Reports Positive Results for Litifilimab in Lupus Study
- Clinical Trial Success: Biogen's AMETHYST Phase 2/3 study of litifilimab demonstrated a statistically significant 11.8% reduction in skin disease activity compared to placebo at Week 16, indicating the potential for the drug to become the first innovative therapy for cutaneous lupus erythematosus in 70 years.
- Efficacy Assessment: The study revealed rapid and sustained improvements in skin disease activity over 24 weeks, with separation from placebo observed as early as Week 4, and a higher proportion of participants achieving CLASI-50 and CLASI-70 responses, underscoring the drug's effectiveness.
- Safety Profile: Over 24 weeks, adverse events occurred in 74.6% of litifilimab participants compared to 64.7% in the placebo group, with most events being mild to moderate; however, serious adverse events were reported in 6.8% of the litifilimab group, higher than the 2.9% in the placebo group.
- Market Reaction: Although Biogen's stock fell by 3.78% to $183.84 on March 27, it rebounded to $185.01 in after-hours trading, reflecting optimistic market sentiment regarding the drug's prospects.
See More
US Stocks Rise as Oil Prices Hit Three-Week High
- Market Gains: The S&P 500 Index rose by 0.58%, the Dow Jones Industrial Average increased by 0.91%, and the Nasdaq 100 Index climbed by 0.30%, reflecting a positive market sentiment amid expectations that the Fed may keep interest rates unchanged.
- Declining Bond Yields: The 10-year Treasury note yield fell by 10 basis points to 4.33%, driven by concerns that the ongoing war in the Middle East could lead to a fuel shortage, potentially hindering global economic growth and influencing the Fed's future rate decisions.
- Rising Oil Prices: Crude oil prices surged over 2% to a three-week high due to Iranian attacks on shipping, raising fears that the closure of the Strait of Hormuz could disrupt global oil and gas supplies, which may lead to significant price increases.
- Manufacturing Activity Decline: The Dallas Fed's manufacturing activity survey dropped by 0.4 to -0.2, falling short of the expected increase to 2.0, indicating signs of economic slowdown that could impact future investment decisions.
See More
FDA Approves Biogen's New High-Dose Spinraza Regimen
- New Dosage Regimen: The US FDA has approved Biogen's new high-dose regimen for Spinraza, consisting of 50 mg/5 mL and 28 mg/5 mL doses, significantly enhancing treatment flexibility and efficacy.
- Accelerated Loading Phase: The new regimen allows individuals new to treatment to receive two 50 mg high-dose injections 14 days apart, followed by 28 mg maintenance doses every four months, thereby accelerating patient treatment progress.
- Transition for Low-Dose Patients: Patients switching from the low-dose regimen will follow their current dosing schedule every four months after a single high-dose loading phase, ensuring continuity and stability in their treatment.
- Clinical Study Support: The approval is supported by results from the phase 2/3 DEVOTE study, demonstrating significant advantages in treatment outcomes with the new dosing regimen, further solidifying Biogen's market position in spinal muscular atrophy.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: Biogen announced that its High Dose SPINRAZA (nusinersen) has been approved by the U.S. FDA for the treatment of spinal muscular atrophy (SMA), backed by over 10 years of clinical data to address ongoing community needs.
- Innovative Dosage Design: The high dose regimen includes 50 mg/5 mL and 28 mg/5 mL doses, designed to deliver a higher concentration of the drug through an accelerated loading phase and maintenance dosing, enabling faster treatment initiation for new patients.
- Clinical Trial Support: The FDA approval is based on data from the three-part Phase 2/3 DEVOTE study, which showed that treatment-naïve symptomatic infants receiving High Dose SPINRAZA experienced statistically significant improvements in motor function compared to a matched sham group from the ENDEAR study, demonstrating the treatment's efficacy.
- Broad Market Outlook: High Dose SPINRAZA will be available in the U.S. in the coming weeks and is also approved in the European Union, Switzerland, and Japan, expected to provide new treatment options for SMA patients globally, further solidifying Biogen's leadership in the neuromuscular disease space.
See More
FDA Approves High Dose SPINRAZA for SMA Treatment
- FDA Approval: The U.S. FDA has approved the High Dose SPINRAZA (nusinersen), which includes 50 mg/5 mL and 28 mg/5 mL doses, aimed at providing a more effective treatment option for spinal muscular atrophy (SMA) patients, with availability expected in the coming weeks, marking a significant advancement in the treatment landscape.
- Clinical Data Support: The high dose regimen is backed by clinical data from the DEVOTE study, which demonstrated statistically significant improvements in motor function for treatment-naïve infants, with a mean difference of 26.19 points on the CHOP-INTEND scale (+15.1 vs. -11.1, p<0.0001), offering new hope for SMA patients.
- Optimized Treatment Protocol: The new regimen features an accelerated loading phase, allowing treatment-naïve patients to receive two 50 mg injections 14 days apart, followed by 28 mg maintenance doses every four months, designed to enhance treatment convenience and effectiveness to meet urgent patient needs.
- Global Expansion: High Dose SPINRAZA has not only been approved in the U.S. but also in the European Union, Switzerland, and Japan, with Biogen collaborating with global regulatory authorities to advance this new treatment option to meet the diverse needs of SMA patients.
See More
